Researchers from the Université de Montréal in Canada have created and verified a new class of DNA-based drug transporters that are 20,000 times smaller than a human hair and could enhance cancer treatment and other diseases.
Optimal Dosing at All Times: A Medical Challenge
Providing and maintaining a therapeutic drug dosage during treatment is one of the most important factors in the successful treatment of disease. Overexposure raises side effects whereas sub-optimal therapeutic exposure decreases effectiveness and often results in drug resistance.
Modern medicine continues to struggle with maintaining the ideal drug concentration level in the blood. Patients must take numerous doses at regular intervals since most drugs degrade quickly, and they frequently forget to do so. The drug concentration in each patient’s blood also varies considerably because each has a unique pharmacokinetic profile.
Alexis Vallée-Bélisle, an Associate Professor of Chemistry at the Université de Montréal and a specialist in bio-inspired nanotechnologies, began to investigate how biological systems control and maintain the concentration of biomolecules after noticing that only about 50% of cancer patients receive the ideal drug dosage during certain chemotherapy.
We have found that living organisms employ protein transporters that are programmed to maintain precise concentration of key molecules such as thyroid hormones, and that the strength of the interaction between these transporters and their molecules dictates the precise concentration of the free molecule.
Alexis Vallée-Bélisle, Associate Professor, Chemistry, Université de Montréal
This simple and direct notion prompted Valléé-Belisle and his research group to create synthetic drug transporters that mimic the natural effect of preserving a precise drug concentration during treatment. Valléé-Belisle holds a Canada Research Chair in bioengineering and bionanotechnology.
Arnaud Desrosiers, a Ph.D. student at UdeM, is the study’s first author. He discovered and created two DNA transporters: one for the antimalarial quinine and the other for the chemical doxorubicin, frequently used to treat leukemia and breast cancer.
He went on to show how these synthetic transporters could be easily set up to deliver and maintain any desired drug concentration.
More interestingly, we also found that these nanotransporters could also be employed as a drug reservoir to prolong the effect of the drug and minimize its dosage during treatment. Another impressive feature of these nanotransporters is that they can be directed to specific parts of the body where the drug is most needed – and that, in principle, should reduce most side effects.
Arnaud Desrosiers, Study First Author and PhD Student, Université de Montréal
Nanotreated Mice: Reduced Cardiotoxicity
The researchers collaborated with Jeanne Leblond-Chain, a pharmacist at the Université de Bordeaux in France, Luc DesGroseillers, a biochemist at the Université de Montréal, Jérémie Berdugo, a pathologist at the Université de Montréal, Céline Fiset, a pharmacist at the Montreal Heart Institute, and Vincent De Guire, a clinical biochemist at the Maisonneuve-Rosemont Hospital, which is affiliated with Université de Montréal, to show the effectiveness of these nanotransporters.
The team found that a particular drug-transporter formulation enables doxorubicin to be kept in circulation and significantly inhibits its diffusion toward important organs like the heart, lungs, and pancreas.
This formulation kept doxorubicin in the blood of mice 18 times longer than usual and minimized cardiotoxicity, keeping the mice healthier as indicated by their normal weight gain.
Vallée-Bélisle stated, “Another great property of our nanotransporters is their high versatility. For now, we have demonstrated the working principle of these nanotransporters for two different drugs. But thanks to the high programmability of DNA and protein chemistries, one can now design these transporters to precisely deliver a wide range of therapeutic molecules.”
He further added, “Additionally, these transporters could also be combined with human-designed liposomic transporters that are now being employed to deliver drugs at various rates.”
A Clinical Study for Blood Cancers?
The scientists are now eager to confirm if their discovery works clinically. They believe their doxorubicin nanotransporter could be useful in treating blood cancers since it is designed to keep the drug in blood circulation as effectively as possible.
“We envision that similar nanotransporters may also be developed to deliver drugs to other specific locations in the body and maximize the presence of the drug at tumor sites. This would drastically improve the efficiency of drugs as well as decrease their side effects.”
The National Science and Engineering Research Council of Canada, the Canada Research Chairs, Les Fonds de recherche du Québec – Nature et technologies, and Le regroupement québécois de research sur la fonction, l’ingénierie et les applications des protéines (PROTEO) provided funding for this study.
News
Scientists Melt Cancer’s Hidden “Power Hubs” and Stop Tumor Growth
Researchers discovered that in a rare kidney cancer, RNA builds droplet-like hubs that act as growth control centers inside tumor cells. By engineering a molecular switch to dissolve these hubs, they were able to halt cancer [...]
Platelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness. Scientists have found a way to improve the performance of brain-computer interface (BCI) electrodes by delivering anti-inflammatory drugs directly [...]
After 150 years, a new chapter in cancer therapy is finally beginning
For decades, researchers have been looking for ways to destroy cancer cells in a targeted manner without further weakening the body. But for many patients whose immune system is severely impaired by chemotherapy or radiation, [...]
Older chemical libraries show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, University of California San Diego scientists and an international team of [...]
Lower doses of immunotherapy for skin cancer give better results, study suggests
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National [...]
Researchers highlight five pathways through which microplastics can harm the brain
Microplastics could be fueling neurodegenerative diseases like Alzheimer's and Parkinson's, with a new study highlighting five ways microplastics can trigger inflammation and damage in the brain. More than 57 million people live with dementia, [...]
Tiny Metal Nanodots Obliterate Cancer Cells While Largely Sparing Healthy Tissue
Scientists have developed tiny metal-oxide particles that push cancer cells past their stress limits while sparing healthy tissue. An international team led by RMIT University has developed tiny particles called nanodots, crafted from a metallic compound, [...]
Gold Nanoclusters Could Supercharge Quantum Computers
Researchers found that gold “super atoms” can behave like the atoms in top-tier quantum systems—only far easier to scale. These tiny clusters can be customized at the molecular level, offering a powerful, tunable foundation [...]
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
WASHINGTON -- A single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer, researchers reported Wednesday. HPV, or human papillomavirus, is very common and spread [...]
New technique overcomes technological barrier in 3D brain imaging
Scientists at the Swiss Light Source SLS have succeeded in mapping a piece of brain tissue in 3D at unprecedented resolution using X-rays, non-destructively. The breakthrough overcomes a long-standing technological barrier that had limited [...]
Scientists Uncover Hidden Blood Pattern in Long COVID
Researchers found persistent microclot and NET structures in Long COVID blood that may explain long-lasting symptoms. Researchers examining Long COVID have identified a structural connection between circulating microclots and neutrophil extracellular traps (NETs). The [...]
This Cellular Trick Helps Cancer Spread, but Could Also Stop It
Groups of normal cbiells can sense far into their surroundings, helping explain cancer cell migration. Understanding this ability could lead to new ways to limit tumor spread. The tale of the princess and the [...]
New mRNA therapy targets drug-resistant pneumonia
Bacteria that multiply on surfaces are a major headache in health care when they gain a foothold on, for example, implants or in catheters. Researchers at Chalmers University of Technology in Sweden have found [...]
Current Heart Health Guidelines Are Failing To Catch a Deadly Genetic Killer
New research reveals that standard screening misses most people with a common inherited cholesterol disorder. A Mayo Clinic study reports that current genetic screening guidelines overlook most people who have familial hypercholesterolemia, an inherited disorder that [...]
Scientists Identify the Evolutionary “Purpose” of Consciousness
Summary: Researchers at Ruhr University Bochum explore why consciousness evolved and why different species developed it in distinct ways. By comparing humans with birds, they show that complex awareness may arise through different neural architectures yet [...]
Novel mRNA therapy curbs antibiotic-resistant infections in preclinical lung models
Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, published in Nature Biotechnology, show that in [...]
